ImmunoCellular Therapeutics, EBIT

ImmunoCellular Therapeutics, (IMUC) currently reports a EBIT of $-550K as of September 2023. That compares with $-2.2M in the prior-year period — up 74.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore ImmunoCellular Therapeutics,'s EBIT history and peer comparisons.

ImmunoCellular Therapeutics,'s EBIT increased from $-2.2M to $-550K — a 74.5% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoCellular Therapeutics,'s EBIT of $-550K is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ImmunoCellular Therapeutics, reported $-550K in EBIT as of September 2023. That compares with $-2.2M in the prior-year period — up 74.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-550K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for ImmunoCellular Therapeutics,, and consider following IMUC for alerts when major investors trade the stock.